NCT03890744: ModraDoc006/r in Patients With Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with confirmed leptomeningeal metastases or with unstable symptomatic brain metastases- see trial for details; Patients with previous treatment of a taxane for recurrent or MBC; Patients with 3+ lines of chemotherapy

Comments are closed.

Up ↑